$SRTS
Sensus Healthcare, Inc.

2024 Q4 Form 10-Q Financial Statement

#000121390024098193 Filed on November 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $8.839M
YoY Change 126.76%
Cost Of Revenue $3.599M
YoY Change 88.53%
Gross Profit $5.240M
YoY Change 163.45%
Gross Profit Margin 59.28%
Selling, General & Admin $2.882M
YoY Change 2.89%
% of Gross Profit 55.0%
Research & Development $863.0K
YoY Change -20.31%
% of Gross Profit 16.47%
Depreciation & Amortization $53.00K
YoY Change -11.67%
% of Gross Profit 1.01%
Operating Expenses $3.745M
YoY Change -3.58%
Operating Profit $1.495M
YoY Change -178.89%
Interest Expense $279.0K
YoY Change
% of Operating Profit 18.66%
Other Income/Expense, Net $279.0K
YoY Change -12.54%
Pretax Income $1.774M
YoY Change -212.56%
Income Tax $559.0K
% Of Pretax Income 31.51%
Net Earnings $1.215M
YoY Change -183.74%
Net Earnings / Revenue 13.75%
Basic Earnings Per Share $0.07
Diluted Earnings Per Share $0.07
COMMON SHARES
Basic Shares Outstanding 16.39M shares 16.39M shares
Diluted Shares Outstanding 16.35M shares

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $22.56M
YoY Change 10.09%
Cash & Equivalents $22.56M
Short-Term Investments
Other Short-Term Assets $1.596M
YoY Change 19.1%
Inventory $11.97M
Prepaid Expenses $1.700M
Receivables $16.96M
Other Receivables $0.00
Total Short-Term Assets $54.81M
YoY Change 19.51%
LONG-TERM ASSETS
Property, Plant & Equipment $1.635M
YoY Change 288.36%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $590.0K
YoY Change 109.96%
Total Long-Term Assets $5.052M
YoY Change 7.76%
TOTAL ASSETS
Total Short-Term Assets $54.81M
Total Long-Term Assets $5.052M
Total Assets $59.86M
YoY Change 18.42%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.973M
YoY Change -0.68%
Accrued Expenses $200.0K
YoY Change 11.11%
Deferred Revenue $686.0K
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $5.210M
YoY Change -0.4%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $517.0K
YoY Change -29.18%
Total Long-Term Liabilities $517.0K
YoY Change -29.18%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.210M
Total Long-Term Liabilities $517.0K
Total Liabilities $5.727M
YoY Change -3.89%
SHAREHOLDERS EQUITY
Retained Earnings $11.89M
YoY Change 361.31%
Common Stock $169.0K
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost) $3.566M
YoY Change 1.54%
Treasury Stock Shares
Shareholders Equity $54.13M
YoY Change
Total Liabilities & Shareholders Equity $59.86M
YoY Change 18.42%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income $1.215M
YoY Change -183.74%
Depreciation, Depletion And Amortization $53.00K
YoY Change -11.67%
Cash From Operating Activities $3.953M
YoY Change 778.44%
INVESTING ACTIVITIES
Capital Expenditures $337.0K
YoY Change 3270.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$337.0K
YoY Change -1223.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -30.00K
YoY Change -25.0%
NET CHANGE
Cash From Operating Activities 3.953M
Cash From Investing Activities -337.0K
Cash From Financing Activities -30.00K
Net Change In Cash 3.586M
YoY Change 715.0%
FREE CASH FLOW
Cash From Operating Activities $3.953M
Capital Expenditures $337.0K
Free Cash Flow $3.616M
YoY Change 721.82%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2024Q3 us-gaap Taxes Payable Current
TaxesPayableCurrent
usd
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Trading Symbol
TradingSymbol
SRTS
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37714
dei Entity Registrant Name
EntityRegistrantName
Sensus Healthcare, Inc.
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
27-1647271
dei Entity Address Address Line1
EntityAddressAddressLine1
851 Broken Sound Pkwy
dei Entity Address Address Line2
EntityAddressAddressLine2
NW #215
dei Entity Address City Or Town
EntityAddressCityOrTown
Boca Raton
dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
33487
dei City Area Code
CityAreaCode
(561)
dei Local Phone Number
LocalPhoneNumber
922-5808
dei Security12b Title
Security12bTitle
Common Stock, par value $0.01 per share
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
16390051 shares
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
22558000 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
23148000 usd
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
16961000 usd
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
10645000 usd
CY2024Q3 us-gaap Inventory Net
InventoryNet
11968000 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
11861000 usd
CY2024Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1723000 usd
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2986000 usd
CY2024Q3 us-gaap Other Assets Current
OtherAssetsCurrent
1596000 usd
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
888000 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
54806000 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
49528000 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1635000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
464000 usd
CY2024Q3 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
2197000 usd
CY2023Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
2140000 usd
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
630000 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
774000 usd
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
590000 usd
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
804000 usd
CY2024Q3 us-gaap Assets
Assets
59858000 usd
CY2023Q4 us-gaap Assets
Assets
53710000 usd
CY2024Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
3973000 usd
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2793000 usd
CY2024Q3 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
351000 usd
CY2023Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
538000 usd
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
200000 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
187000 usd
CY2023Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
37000 usd
CY2024Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
686000 usd
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
657000 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
5210000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4212000 usd
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
451000 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
596000 usd
CY2024Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
66000 usd
CY2023Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
60000 usd
CY2024Q3 us-gaap Liabilities
Liabilities
5727000 usd
CY2023Q4 us-gaap Liabilities
Liabilities
4868000 usd
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
16930845 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
16390051 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
16907095 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
16374171 shares
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
169000 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
169000 usd
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
45640000 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
45405000 usd
CY2024Q3 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
540794 shares
CY2023Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
532924 shares
CY2024Q3 us-gaap Treasury Stock Value
TreasuryStockValue
3566000 usd
CY2023Q4 us-gaap Treasury Stock Value
TreasuryStockValue
3519000 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
11888000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
6787000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
54131000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
48842000 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
59858000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
53710000 usd
CY2024Q3 us-gaap Revenues
Revenues
8839000 usd
CY2023Q3 us-gaap Revenues
Revenues
3898000 usd
us-gaap Revenues
Revenues
28741000 usd
us-gaap Revenues
Revenues
11838000 usd
CY2024Q3 us-gaap Cost Of Revenue
CostOfRevenue
3599000 usd
CY2023Q3 us-gaap Cost Of Revenue
CostOfRevenue
1909000 usd
us-gaap Cost Of Revenue
CostOfRevenue
11416000 usd
us-gaap Cost Of Revenue
CostOfRevenue
5609000 usd
CY2024Q3 us-gaap Gross Profit
GrossProfit
5240000 usd
CY2023Q3 us-gaap Gross Profit
GrossProfit
1989000 usd
us-gaap Gross Profit
GrossProfit
17325000 usd
us-gaap Gross Profit
GrossProfit
6229000 usd
CY2024Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1309000 usd
CY2023Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1290000 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
3575000 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
4983000 usd
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1573000 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1511000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4731000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4204000 usd
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
863000 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1083000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2655000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3001000 usd
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
3745000 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
3884000 usd
us-gaap Operating Expenses
OperatingExpenses
10961000 usd
us-gaap Operating Expenses
OperatingExpenses
12188000 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
1495000 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1895000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
6364000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-5959000 usd
CY2023Q3 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
42000 usd
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
42000 usd
CY2024Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
279000 usd
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
277000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
702000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
764000 usd
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
279000 usd
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
319000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
702000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
806000 usd
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
1774000 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1576000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
7066000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5153000 usd
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
559000 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-125000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1965000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1428000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
1215000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-1451000 usd
us-gaap Net Income Loss
NetIncomeLoss
5101000 usd
us-gaap Net Income Loss
NetIncomeLoss
-3725000 usd
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.07
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.09
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.31
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.23
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.07
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.09
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.31
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.23
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
16321131 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
16270403 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
16304913 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
16255263 shares
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
16345749 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
16270403 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
16332485 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
16255263 shares
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
48069000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
161000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
46000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
18000 usd
CY2023Q1 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
-40000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-1894000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
46324000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
67000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
1000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-380000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
46010000 usd
CY2023Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
67000 usd
CY2023Q3 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
-12000 usd
CY2023Q3 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
27000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-1451000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
44587000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
48842000 usd
CY2024Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
92000 usd
CY2024Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
1000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
2274000 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
51207000 usd
CY2024Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
66000 usd
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
17000 usd
CY2024Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
1000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
1612000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
52901000 usd
CY2024Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
45000 usd
CY2024Q3 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
-47000 usd
CY2024Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
17000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
1215000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
54131000 usd
us-gaap Net Income Loss
NetIncomeLoss
5101000 usd
us-gaap Net Income Loss
NetIncomeLoss
-3725000 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
123000 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
7000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
154000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
216000 usd
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
42000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
144000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
139000 usd
srts Provision For Product Warranties
ProvisionForProductWarranties
-81000 usd
srts Provision For Product Warranties
ProvisionForProductWarranties
-325000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
201000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
276000 usd
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-57000 usd
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-1428000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
6439000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-10409000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
859000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
9818000 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-1263000 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-2315000 usd
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
708000 usd
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
680000 usd
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-214000 usd
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-187000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1180000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1522000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-132000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-152000 usd
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-37000 usd
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-890000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
35000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-44000 usd
srts Increase Decrease Product Warranties
IncreaseDecreaseProductWarranties
268000 usd
srts Increase Decrease Product Warranties
IncreaseDecreaseProductWarranties
386000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4813000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
573000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
229000 usd
us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
42000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-573000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-187000 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
27000 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
47000 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
52000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
34000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
46000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-13000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-33000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-590000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-5033000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
23148000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
25520000 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
22558000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
20487000 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
2474000 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
1440000 usd
srts Transfer Of Inventory To Property And Equipment
TransferOfInventoryToPropertyAndEquipment
752000 usd
srts Transfer Of Inventory To Property And Equipment
TransferOfInventoryToPropertyAndEquipment
117000 usd
us-gaap Use Of Estimates
UseOfEstimates
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-variant: small-caps"><b><i>Use of Estimates</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, including disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expense during the reporting periods. Actual results could differ from those estimates.</p>
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-variant: small-caps"><b><i>Reclassification of Prior Year Presentation</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain prior period amounts have been reclassified for consistency with the current period presentation. The reclassifications are limited to the condensed consolidated statements of cash flow and have no impact on the reported results of operations.</p>
CY2024Q3 us-gaap Revenues
Revenues
8839000 usd
CY2023Q3 us-gaap Revenues
Revenues
3898000 usd
us-gaap Revenues
Revenues
28741000 usd
us-gaap Revenues
Revenues
11838000 usd
CY2023Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
717000 usd
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
-2680000 usd
srts Contract With Customer Liability Amounts Invoiced
ContractWithCustomerLiabilityAmountsInvoiced
2715000 usd
CY2024Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
752000 usd
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-variant: small-caps"><b><i>Concentration</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash and cash equivalents and accounts receivable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">One customer in the U.S. accounted for 65% and 52% of revenue for the three months ended September 30, 2024 and 2023, respectively, 74% and 52% of revenue for the nine months ended September 30, 2024 and 2023, respectively, and 88% and 85% of the accounts receivable as of September 30, 2024 and December 31, 2023, respectively.</p>
CY2024Q3 us-gaap Revenues
Revenues
8839000 usd
CY2023Q3 us-gaap Revenues
Revenues
3898000 usd
us-gaap Revenues
Revenues
28741000 usd
us-gaap Revenues
Revenues
11838000 usd
us-gaap Allowance For Doubtful Accounts Receivable Period Increase Decrease
AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease
123000 usd
CY2023 us-gaap Allowance For Doubtful Accounts Receivable Period Increase Decrease
AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease
0 usd
CY2024Q3 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
81000 usd
CY2023Q3 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
2000 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
123000 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
7000 usd
CY2024Q3 srts Revenues From Non Lease Components
RevenuesFromNonLeaseComponents
97000 usd
srts Revenues From Non Lease Components
RevenuesFromNonLeaseComponents
147000 usd
CY2024Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3438000 usd
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2347000 usd
CY2024Q3 us-gaap Construction In Progress Gross
ConstructionInProgressGross
228000 usd
CY2024Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2031000 usd
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1883000 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1635000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
464000 usd
CY2024Q3 us-gaap Depreciation
Depreciation
53000 usd
CY2023Q3 us-gaap Depreciation
Depreciation
60000 usd
us-gaap Depreciation
Depreciation
154000 usd
us-gaap Depreciation
Depreciation
167000 usd
CY2022Q4 us-gaap Line Of Credit Facility Maximum Borrowing Capacity
LineOfCreditFacilityMaximumBorrowingCapacity
7500000 usd
CY2024Q3 us-gaap Line Of Credit Facility Current Borrowing Capacity
LineOfCreditFacilityCurrentBorrowingCapacity
10000000 usd
us-gaap Line Of Credit Facility Interest Rate During Period
LineOfCreditFacilityInterestRateDuringPeriod
0.0746 pure
us-gaap Line Of Credit Facility Asset Restrictions
LineOfCreditFacilityAssetRestrictions
$3,500,000
us-gaap Line Of Credit Facility Maximum Amount Outstanding During Period
LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod
15000000 usd
CY2023Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
538000 usd
CY2024Q3 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
81000 usd
us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
268000 usd
CY2024Q3 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
351000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
57000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
229000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
236000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
181000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
703000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
52000 usd
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
651000 usd
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
200000 usd
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
451000 usd
CY2024Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y
CY2024Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.05 pure
us-gaap Operating Lease Payments Use
OperatingLeasePaymentsUse
132000 usd
us-gaap Operating Lease Payments Use
OperatingLeasePaymentsUse
152000 usd
CY2024Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
57000 usd
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
57000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
171000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
171000 usd
CY2024Q3 us-gaap Operating Lease Lease Income
OperatingLeaseLeaseIncome
75000 usd
us-gaap Operating Lease Lease Income
OperatingLeaseLeaseIncome
116000 usd
CY2024Q3 us-gaap Lessor Operating Lease Payments To Be Received Remainder Of Fiscal Year
LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear
99000 usd
CY2024Q3 us-gaap Lessor Operating Lease Payments To Be Received Next Twelve Months
LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths
396000 usd
CY2024Q3 us-gaap Lessor Operating Lease Payments To Be Received Two Years
LessorOperatingLeasePaymentsToBeReceivedTwoYears
396000 usd
CY2024Q3 us-gaap Lessor Operating Lease Payments To Be Received Three Years
LessorOperatingLeasePaymentsToBeReceivedThreeYears
396000 usd
CY2024Q3 us-gaap Lessor Operating Lease Payments To Be Received Four Years
LessorOperatingLeasePaymentsToBeReceivedFourYears
396000 usd
CY2024Q3 us-gaap Lessor Operating Lease Payments To Be Received Thereafter
LessorOperatingLeasePaymentsToBeReceivedThereafter
576000 usd
CY2024Q3 us-gaap Lessor Operating Lease Payments To Be Received
LessorOperatingLeasePaymentsToBeReceived
2259000 usd
CY2024Q3 srts Paymentof Inventory Finished Goods
PaymentofInventoryFinishedGoods
200000 usd
CY2023Q3 srts Paymentof Inventory Finished Goods
PaymentofInventoryFinishedGoods
1300000 usd
srts Paymentof Inventory Finished Goods
PaymentofInventoryFinishedGoods
5900000 usd
srts Paymentof Inventory Finished Goods
PaymentofInventoryFinishedGoods
9200000 usd
CY2024Q3 srts Finished Goods Received
FinishedGoodsReceived
2600000 usd
CY2023Q3 srts Finished Goods Received
FinishedGoodsReceived
3500000 usd
srts Finished Goods Received
FinishedGoodsReceived
7800000 usd
srts Finished Goods Received
FinishedGoodsReceived
11200000 usd
CY2024Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1700000 usd
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
3000000 usd
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
295223 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
312973 shares
CY2022Q4 srts Restricted Vest Percentage
RestrictedVestPercentage
0.25 pure
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
2250
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
8.96
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
0 usd
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
0 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
19000 usd
CY2024Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
257000 usd
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y1M6D
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
559000 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-125000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1965000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1428000 usd
CY2024Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.315 pure
CY2023Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.079 pure
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.278 pure
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.277 pure
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
usd
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
usd
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
usd
us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
usd
us-gaap Interest Paid Net
InterestPaidNet
usd
us-gaap Interest Paid Net
InterestPaidNet
usd
CY2023Q4 us-gaap Construction In Progress Gross
ConstructionInProgressGross
usd
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001494891

Files In Submission

Name View Source Status
0001213900-24-098193-index-headers.html Edgar Link pending
0001213900-24-098193-index.html Edgar Link pending
0001213900-24-098193.txt Edgar Link pending
0001213900-24-098193-xbrl.zip Edgar Link pending
ea0220679-10q_sensus.htm Edgar Link pending
ea022067901ex10-1_sensus.htm Edgar Link pending
ea022067901ex10-2_sensus.htm Edgar Link pending
ea022067901ex31-1_sensus.htm Edgar Link pending
ea022067901ex31-2_sensus.htm Edgar Link pending
ea022067901ex32-1_sensus.htm Edgar Link pending
ea022067901ex32-2_sensus.htm Edgar Link pending
ex10-1_001.jpg Edgar Link pending
ex10-2_001.jpg Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
ea0220679-10q_sensus_htm.xml Edgar Link completed
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
srts-20240930.xsd Edgar Link pending
srts-20240930_cal.xml Edgar Link unprocessable
srts-20240930_def.xml Edgar Link unprocessable
srts-20240930_lab.xml Edgar Link unprocessable
srts-20240930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable